Previous 10 |
Antares Pharma (NASDAQ: ATRS ): Q4 EPS of $0.04 may not be comparable to consensus of -$0.03. More news on: Antares Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today reported unaudited consolida...
EWING, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40 th Annual Institutional Investors Conference on Tuesday March 5, 2019 at 10:...
EWING, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter and full year 2018 financial results and recent operating progress before the market opens on Thursday, February 28, 2019. Management will host a webca...
Insys Therapeutics ( INSY ) has had an agonizing past two years due to the combination of financial and legal troubles. Federal investigations into the company and former executives have hurt sales, which in turn, has decimated the share price. However, the sales of its flagship commercial p...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...